baber/WOPTO huggingface dataset:
Patent NZ-569469-A (NZ)
Title: Method of inhibiting remnant lipoprotein production
Inventor: OKAMOTO HIROSHI
IPC: A61K31/167
Filed: 2004-09-24
Abstract: Disclosed is the use of an effective amount of trans-(4-([N-{[N'-[3,5-bis(trifluoromethyl)benzyl]-N'-(2-methyl-2H-tetrazol-5-yl)amino]methyl}-5-methyl-4-trifluoromethylphenyl)-N-ethylamino]methyl)cyclohexyl) acetic acid or a pharmaceutically acceptable salt thereof or a compound of formula IX wherein the substituents are disclosed within the specification or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier in the preparation of a medicament for the treatment or prevention of hyperlipidemia or arteriosclerosis or hyper-remnant lipoproteinemia in a patient. (62) Divided Out of 546732
Patent NZ-573349-A (NZ)
Title: Cap for injection device characterised by the movement mechanism for grip means and retention means
Inventor: JENNINGS DOUGLAS IVAN
IPC: A61M5/32
Filed: 2007-05-29
Abstract: A cap (130) for an injection device is disclosed. The injection device houses a syringe having a syringe body (116) and a needle. The needle is sealed by a boot (118). The cap (130) is arranged so that the boot (118) can be connected to the cap (130) whilst exerting a minimal force on the syringe, but cannot be removed from the cap (130) without applying significantly greater force to the syringe. The cap (130) and housing that houses the syringe body (116) are arranged so that upon removal of the cap (130) from the housing, the boot (118) is removed from the syringe.
Patent NZ-574283-A (NZ)
Title: Electrochemical cell with positive container
Inventor: MARPLE JACK W
IPC: H01M4/136
Filed: 2007-07-25
Abstract: Disclosed herein is an electrochemical cell, particularly an electrochemical cell having a container with a positive polarity. The electrochemical cell includes: · a container having an open end; · a positive electrode comprising iron disulfide; · a negative electrode comprising lithium; · a non-aqueous electrolyte; · a separator disposed between the positive electrode and the negative electrode, wherein the separator, the electrolyte, the positive electrode and the negative electrode are disposed in the container; · a cover enclosing the open end of the container, said cover not making an electrical contact with the container; · an electrically conductive member that is compressively held between the negative electrode and the cover, and · wherein the positive electrode makes electrical contact with the container and the negative electrode makes electrical contact with a portion of the cover.
Patent NZ-582013-A (NZ)
Title: Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
Inventor: HORMANN ROBERT E
IPC: C07C241/00
Filed: 2008-05-29
Abstract: The disclosure relates to diacylhydrazine compounds of formula (II) for use with ecdysone receptor-based inducible gene expression systems, wherein the variables shown in formula (II) are as defined in the specification. These compounds are useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable, thereby it advantageously provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.
Patent NZ-585715-A (NZ)
Title: Recombinantly modified plasmin
Inventor: NOVOKHATNY VALERY
IPC: C12N15/09
Filed: 2008-11-25
Abstract: A recombinantly modified plasminogen polypeptide that has at least 95% sequence identity to SEQ ID NO: 2 and comprises: (a) a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen, wherein the last four amino acids residues within the kringle domain are V, P, Q and C; and (b) a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen. The polypeptide is able to bind to immobilised lysine and can be cleaved into plasmin by contacting the polypeptide with a protease. The polypeptide can be more effectively produced in bacterial cells, for example E. coli, than native plasminogen.
Patent NZ-586912-A (NZ)
Title: Walking aid as exoskeleton from pelvic support down to foot supports to power assist walking for a user
Inventor: LITTLE RICHARD
IPC: A61F5/00
Filed: 2008-12-24
Abstract: 586912 According to a first aspect there is provided a walking aid (WA) (100) usable as a medical device, suitable for supporting a mobility impaired disabled user while moving through a set of movements correlating to a walking motion. The WA (100) comprises an exoskeleton (500), a power source in the form of a battery pack or other similar onboard power pack (not shown) together with its associated power supply cables (not shown), and a control system (not shown). an The exoskeleton (500) comprises a rigid pelvic support member or hip frame (15) including a pelvic harness, and a pair of leg structures (a first leg structure and second leg structure). Each of the leg structures comprise an upper leg structural member (10), a lower leg structural member (11), a foot member (18), a main hip actuator, a knee actuator (13) and a main foot actuator (19). The upper leg structural member (10) is for securing with an upper leg of a user, the upper leg structural member (10) being pivotally engaged at a first end thereof to the hip frame (15) by the hip joint. The lower leg structural member (11) is for securing with the lower leg of the user, the lower leg structural member (11) being pivotally engaged at a first end thereof to a second end of the upper leg structural member (10) by a knee joint (12). At a first end (10) of the upper leg member (10) is a hip joint that pivotally engages the upper leg member (10) with the hip frame (15). The hip joint defines a hip axis that in use is located relative to the user at or approximate to the natural axis of hip rotation in an anterior/posterior direction of movement. In a preferred embodiment, each hip joint is configured relative to the hip frame (15) with its axis of rotation extending downwardly in a lateral direction at an angle of between zero and ten degrees, and more preferably of about four degrees. This inclination of the axis of rotation mimics a human beings upper leg alignment. The inclination allows for more natural transfer of the centre of mass (generally located about the middle of the pelvis) to a point within the support area provided by the foot member (18) during when the WA (100) is controlled in a natural walking movement.
Patent NZ-587422-A (NZ)
Title: Process for generating a hydrocarbon feedstock from lignin
Inventor: SCHINSKI WILLIAM LAWRENCE
IPC: C10G1/00
Filed: 2009-02-23
Abstract: Disclosed herein is a refinery process comprising: hydroprocessing a lignin-containing feedstock to yield a biofuels feedstock, wherein the lignin-containing feedstock comprises lignin separated from black liquor from a pulping process, wherein the lignin is separated from the black liquor from the pulping process by carbon dioxide (CO2) injection and refinery residuals and wherein the biofuels feedstock has been reduced in oxygen content and average molecular weight relative to the lignin as a result of hydroprocessing of the lignin contained therein. Also disclosed is a further refinery process comprising: hydroprocessing a lignin-containing feedstock to yield a biofuels feedstock, wherein the lignin-containing feedstock comprises black liquor from a pulping process, and wherein the biofuels feedstock has been reduced in oxygen content and average molecular weight relative to the lignin as a result of hydroprocessing of the lignin contained therein, and wherein the hydroprocessing produces water containing caustic salts separate from the biofuels feedstock.
Patent NZ-587847-A (NZ)
Title: Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes
Inventor: MAZUROV ANATOLY
IPC: A61P25/00
Filed: 2007-11-01
Abstract: Disclosed is a 3,7-diazabicyclo[3.3.0]octane of Formula I wherein n is 0 or 1; and Cy is a heteroaryl group selected from the group consisting of 2-furanyl, 3-furanyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl and 4-pyridinyl. Also disclosed is the use of said octane in the treatment of age-associated memory impairment, mild cognitive impairment, pre-senile dementia, early onset Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, Lewy body dementia, vascular dementia, Alzheimer's disease, stroke, AIDS dementia complex, attention deficit disorder, attention deficit hyperactivity disorder, dyslexia, schizophrenia, schizophreniform disorder and schizoaffective disorder.
Patent NZ-589247-A (NZ)
Title: Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide
Inventor: LYONS ROBERT T
IPC: A61K9/00
Filed: 2005-05-19
Abstract: Disclosed is an ophthalmic composition comprising an effective amount of a therapeutically active agent, stabilized chlorine dioxide, and citric acid and/or conjugate bases thereof. An example of the stabilised chlorine dioxide is Purite. Also disclosed is a method of stabilising incompatible components of a composition.
Patent NZ-592571-A (NZ)
Title: Aryl piperazine and their use as alpha2c antagonists
Inventor: TOLVANEN ARTO
IPC: C07D319/20
Filed: 2009-11-20
Abstract: ABSTRACT - 592571 The disclosure relates to aryl piperazine derivative compounds of formula (I), wherein the variables X, Z, A, B, D, E, R1-R4 and m are as defined in the specification. These compounds exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists for the treatment of disease or the condition selected from a mental disorder propagated by stress, Parkinson's disease, depression, schizophrenia, attention deficit hyperactivity disorder, post-traumatic stress disorder, obsessive compulsive disorder, Tourette's syndrome, blepharospasm or other focal dystonias, temporal lobe epilepsy with psychosis, a drug-induced psychosis, Huntington's disease, a disorder caused by fluctuation of the levels of sex hormones, panic disorder, Alzheimer's disease or mild cognitive impairment.
Patent NZ-593770-A (NZ)
Title: Compositions for enhancing nail growth
Inventor: WHITCUP SCOTT M
IPC: A61K9/107
Filed: 2010-01-07
Abstract: ABSTRACT - 593770 The disclosure relates to a use of an oil-in-water emulsion comprising a vegetable oil, a cyclosporine A derivative, glycerin, carbomer, and a surfactant in the manufacture of a medicament for use in accelerating nail growth, treating brittle nails and strengthening nails in a human or animal, wherein the medicament is formulated to be topically applied to the fingernails or cuticles of a patient at least once a day, wherein the vegetable oil is selected from the group consisting of: Anise oil; Castor oil; Clove oil; Cassia oil; Cinnamon oil; oils having a specific gravity between 0.90 and 0.95; Almond oil; Corn oil; Arachis oil; Cottonseed oil; Safflower oil; Maize oil; Linseed oil; Rapeseed oil; Soybean oil; Olive oil; Caraway oil; Rosemary oil; Peanut oil; Peppermint oil; Sunflower oil; Eucalyptus oil; Sesame oil; Coriander oil; Lavender oil; Citronella oil; Juniper oil; Lemon oil; Orange oil; Clary sage oil; Nutmeg oil; and, Tea tree oil or mixtures thereof, and wherein the surfactant selected from the group consisting of Polysorbate 80, carboxylated and ethoxylated alcohols, amine oxides, block polymers, fatty acids including carboxylic fatty acids, ethoxylated alkyl phenols, ethoxylated fatty esters, glycerol esters, lanolin-based derivatives, lignin derivatives, methyl esters, mono- and tri-glycerides, polyethylene glycols, polymeric surfactants, propoxylated and ethoxylated fatty acids, alcohols, or alkyl phenols, protein based surfactants, sucrose and glucose esters and derivatives or mixtures thereof.
Patent NZ-593961-A (NZ)
Title: Mist type fire protection devices, systems and methods
Inventor: CONNERY LUKE S
IPC: A62C31/02
Filed: 2010-01-04
Abstract: 593961 Disclosed are various mist-type fire protection systems for the protection of light and ordinary hazard occupancies of reduced water demand as compared to known mist type systems or sprinkler systems configured to protect the same occupancies. Three system configurations are defined by varying design criteria for the installation of: mist devices having an enlarged coverage area alone or in combination with known nozzles or sprinklers. The preferred mist devices provide for the protection of at least one of a light hazard occupancy only and a light and ordinary hazard occupancy having a ceiling with a maximum ceiling height of at least 8 ft. The preferred device include a body having a passageway defining a K-factor of less than 1 gpm/psi1/2. The preferred device includes means for diffusing the fluid at a flux density of less than 0.1 gpm/sq. ft. for a fluid pressure at the inlet of less than 500 psi. to define a coverage area of the device of over than 132 sq. ft., preferably to a maximum of 256 sq. ft.
Patent NZ-594766-A (NZ)
Title: Virtual service provider systems
Inventor: RALEIGH GREGORY G
IPC: G06F9/46
Filed: 2010-01-19
Abstract: 594766 A network system and a method for controlling communication by an end-user device over a roaming network are disclosed. The network system comprises a communication interface and one or more network elements. The communication interface is for enabling the network system to communicate with an end-user device over a first roaming access network available to the end-user device and the end-user device is associated with a service plan. The service plan is associated with a home access network and a first service provider. The home access network is different from the first roaming access network. The first roaming access network is associated with a second service provider. The one or more network elements are configured to determine that the end-user device is connected to the first roaming access network and allow a first set of communications over the first roaming access network. The first set of communications comprises one or more communications to or from the end-user device for presenting, through a user interface of the end-user device, a first notification and for obtaining a user response to the first notification. The first notification is configured to provide information associated with the end-user device being connected to the first roaming access network and to assist in obtaining the user response. The one or more network elements are configured to block a second set of communications over the first roaming access network before obtaining the user response. The second set of communications comprises one or more communications sent to or from the end-user device that are not within the first set of communications. The one or more network elements are configured to obtain the user response and apply an access control policy to a set of one or more subsequent communications over the first roaming access network. The access control policy is based on the user response with the set of one or more subsequent communications being communications to or from the end-user device after the one or more network elements obtain the user response
Patent NZ-595579-A (NZ)
Title: 5-Difluoromethoxy-4-hydroxymethyl-1-methyl-3-trifluoromethyl-pyrazole / (5-(difluoromethoxy)-3-(trifluoromethyl)-1-methyl-1H-pyrazol-4-yl)methanol
Inventor: UCHIDA YUKIO
IPC: C07D231/14
Filed: 2007-02-08
Abstract: 595579 Disclosed is the compound 5-difluoromethoxy-4-hydroxymethyl-1-methyl-3-trifluoromethyl-pyrazole which is also known as (5-difluoromethoxy-3-trifluoromethyl-1-methyl-1H-pyrazol-4-yl)methanol, which is useful as an intermediate for the production of medicines and agricultural chemicals.
Patent NZ-603994-A (NZ)
Title: Nasal assembly
Inventor: HITCHCOCK ROBIN GARTH
IPC: A61M16/08
Filed: 2004-02-20
Abstract: A nasal interface (690) for delivering pressurized breathable gas to a user, comprising: a support frame (708) having a central portion and a pair of lateral support arms (714) extending laterally away from the central portion, each lateral support arm including an integrally formed connector slot; a silicone pillows cushion (712) including a base portion and a pair of nozzles, the pillows cushion being removably coupled with the central portion of the support frame with the pair of nozzles structured to sealingly engage with nasal passages of a user’s nose; an inlet tube (702) having a first end (704) provided with a swivel connector to be connected to a source of pressurized breathable gas via an air delivery tube, and a second end provided to deliver the gas into the support frame for breathing by the user via the pillows cushion; and headgear (692) including a back strap adapted to pass around the rear portion of the user’s head, a top strap adapted to pass over the top of the user’s head, and a pair of depending side straps (698) each of which is suspended from a junction between the back and top straps. The depending side straps are configured to extend forwardly of the ear along the user’s face. Each of the depending side straps has an end received in a respective one of the connector slots of the lateral support arms. Each of the depending side straps includes a hook and loop fastener. The top strap is a coronal strap (696) arranged and configured to engage the user’s corona. The back strap is an occipital strap (694) configured and dimensioned to engage the user’s occiput.
Patent NZ-617582-A (NZ)
Title: Compositions and methods for autologous germline mitochondrial energy transfer
Inventor: TILLY JONATHAN LEE
IPC: C12N5/075
Filed: 2012-04-13
Abstract: Disclosed is a method of preparing an oocyte for in vitro fertilisation (IVF) or artificial insemination, the method comprising transferring a composition comprising i) oogonial stem cell (OSC) mitochondria, or ii) mitochondria isolated from a progeny of an OSC, the OSC having been isolated from ovarian tissue, into an autologous oocyte, thereby preparing the oocyte for IVF or artificial insemination, wherein the OSC is an isolated non-embryonic stem cell that is mitotically competent and expresses Vasa, Oct-4, Dazl, Stella and optionally a stage-specific embryonic antigen.
Patent NZ-627608-A (NZ)
Title: Self priming spackling compound
Inventor: GOZUM JOHN E
IPC: C09K3/10
Filed: 2013-01-16
Abstract: Disclosed herein is a self-priming spackling compound which includes between about 35% by weight and about 65% by weight acrylic latex resin, between about 20% by weight and about 50% by weight filler material, and between about 1 % by weight and about 20% by weight water, wherein the latex resin has an average latex particle size of less than about 0.18 microns. The compound may also have a minimum film formation temperature of less than about 15 degrees Celsius, and/or a glass transition temperature (Tg) of less than about 25 degrees Celsius. To further enhance the self-priming performance of the spackling compound, the formulation may further comprise a colorant such as titanium dioxide.
Patent NZ-711474-A (NZ)
Title: Expandable body device and method of use
Inventor: FRANANO F NICHOLAS
IPC: A61M29/02
Filed: 2014-03-17
Abstract: Disclosed herein are medical devices comprising a single-lobed, thin-walled, expandable body and a flexible, elongated delivery device for treating saccular vascular aneurysms and occluding segments of blood vessels and other biological conduits. The expandable bodies include inter alia a catherter delivery device and a detachable wire to contact the exterior surface of a distal portion of the expanded expandable body, with the detachable wire configured to contact the inner wall surface of the aneurysm opposite the opening to the lumen of the aneurysm where the expandable body entered the lumen of the aneurysm, and wherein, once detached, the detachable wire is configured to remain in the aneurysm. For the treatment of saccular aneurysms, the expandable body may be deployed in combination with one or more coiled wires that contact both the wall of the aneurysm and the expandable body and exert force on the expandable body to aid in sealing the aneurysm neck.
Patent NZ-714997-A (NZ)
Title: Plastic aggregate and its use thereof
Inventor: HUTCHINSON PETER
IPC: B09B3/00
Filed: 2014-11-24
Abstract: The invention generally relates to a method of making a plastic aggregate, and its use to make concrete products. The aggregate is formed by providing a granulated waste plastic material, introducing the granulated waste plastic material into an extruder having a die 1, the die having a ratio of die nozzle open area A to die land area of about 1:10 to about 1:40 - the die land area = nozzle circumference X land length B, and extruding the granulated waste plastic material through the extruder to generate an extruded plastic aggregate, and treating the aggregate with a powdered controlled cooling aid. The method can include the addition of additives and treatment of the surface of the aggregate to produce a desired aggregate that can be used to make a concrete product with desired properties, such as compressive strength and weight.
Patent NZ-735984-A (NZ)
Title: Container having a use-evident device
Inventor: SMITH ROGER
IPC: B65B69/00
Filed: 2013-10-17
Abstract: Many containers are provided with tamper-resistant devices to resist refilling of contents in the containers. However, such containers may not indicate whether the container has been used. Disclosed herein is a package that includes a container having an open end, a closure closing the open end of the container, a sensor carried by at least one of the container or the closure, and a display electrically coupled to the sensor and carried by the container. The sensor is configured to detect weight of product in the container and is responsive to a change in weight of product in the container to irreversibly modify an optical characteristic displayed on the display to indicate that the package has been opened and/or that product has been dispensed from the container. The display exhibits an initial state of the optical characteristic, and then exhibits another state irreversible to the initial state after the package has been opened and/or relieved of at least some of the product in the container. The container may provide evidence of efforts to repackage the container with counterfeit product.
Patent NZ-739883-A (NZ)
Title: 5-ht2c receptor agonists and compositions and methods of use
Inventor: LEHMANN JUERG
IPC: C07D223/32
Filed: 2016-07-28
Abstract: “The present invention relates to fused azepine derivatives which modulate the activity of the 5-HT2C receptor. These derivatives are useful in weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain and type 2 diabetes.”
Patent NZ-742413-A (NZ)
Title: Automated caged bird spray applicator system
Inventor: LESLIE CHRISTOPHER
IPC: A61D1/02
Filed: 2016-10-13
Abstract: The disclosure relates to a spray applicator system for accurately and precisely dosing liquid formulations, including vaccines and probiotic formulations, to birds enclosed in cages, which cages are positioned in a row. In particular, the disclosure relates to spray applicators, having improved acceptance by the avian animals, relative to more disruptive prior spray applicators. The spray applicator system comprises a plurality of nozzle assemblies positioned to direct a spray toward the cages fluidly connected to one another and a pump, a portable pump system comprising a pump, which pump is operatively connected to the nozzle assemblies and operably connected to a portable liquid reservoir. The system is reversibly attachable to a poultry feed system movable along the row.